[{"id":"46c4dafa-648c-4f9b-8154-30165bb2495f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01849146","created_at":"2024-03-06T15:37:16.511Z","updated_at":"2024-07-02T16:35:16.074Z","phase":"Phase 1","brief_title":"Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma","source_id_and_acronym":"NCT01849146","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT • CASP3 • WEE1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • MGMT • CASP3 • WEE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/19/2013","start_date":" 08/19/2013","primary_txt":" Primary completion: 07/29/2021","primary_completion_date":" 07/29/2021","study_txt":" Completion: 03/04/2025","study_completion_date":" 03/04/2025","last_update_posted":"2024-03-06"}]